Franziska Michor - Nov 20, 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
Jonathan D. Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Nov 20, 2024
Transactions value $
$0
Form type
4
Date filed
11/22/2024, 06:25 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award +30.6K 30.6K Nov 20, 2024 Direct F1
transaction RXRX Class A Common Stock Award $0 +15.3K +50.08% $0.00 46K Nov 20, 2024 Direct F2
transaction RXRX Class A Common Stock Award $0 +17.7K +38.5% $0.00 63.6K Nov 20, 2024 Direct F3
transaction RXRX Class A Common Stock Award $0 +41.4K +65.03% $0.00 105K Nov 20, 2024 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Award +30.7K 30.7K Nov 20, 2024 Class A Common Stock 30.7K $6.59 Direct F5, F6
transaction RXRX Stock Option (Right to Buy) Award +15.3K 15.3K Nov 20, 2024 Class A Common Stock 15.3K $7.34 Direct F7, F8
transaction RXRX Stock Option (Right to Buy) Award +17.7K 17.7K Nov 20, 2024 Class A Common Stock 17.7K $6.64 Direct F9, F10
transaction RXRX Stock Option (Right to Buy) Award $0 +82.8K $0.00 82.8K Nov 20, 2024 Class A Common Stock 82.8K $6.04 Direct F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 (1) Received in exchange for [] ordinary shares of Exscientia plc ("Exscientia") in connection with the acquisition of the entire issued and to be issued share capital of Exscientia by Recursion Pharmaceuticals, Inc. ("Recursion") on November 20, 2024 (the "Transaction"). The last closing price on The Nasdaq Stock Market prior to the effective time of the Transaction of (a) the American Depositary Shares ("ADSs") representing ordinary shares of Exscientia was $4.84 per ADS, and (b) Recursion's Class A common stock was $6.27 per share.
F2 Represents restricted stock units ("RSUs") that were exchanged in connection with the Transaction, each RSU representing the right to receive one share of Class A common stock of Recursion. The RSUs vest in equal quarterly installments beginning on November 3, 2024 and continuing through May 3, 2026, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.
F3 Represents RSUs that were exchanged in connection with the Transaction, each RSU representing the right to receive one share of Class A common stock of Recursion. The RSUs will vest onMay 15, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.
F4 Represents a grant of restricted stock units automatically granted pursuant to Recursion's Outside Director Compensation Policy. The restricted stock units will vest as to 1/3rd of the shares subject to the award on the first three anniversaries of November 20, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.
F5 Options vest and become exercisable in equal quarterly installments over a three year period beginning May 3, 2023, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.
F6 Received in the Transaction in exchange for a share option to acquire 39,683 Exscientia ordinary shares for $5.09 per share.
F7 Options vest and become exercisable on May 17, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.
F8 Received in the Transaction in exchange for a share option to acquire 19,778 Exscientia ordinary shares for $5.67 per share.
F9 Options vest and become exercisable on May 15, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.
F10 Received in the Transaction in exchange for a share option to acquire 22,894 Exscientia ordinary shares for $5.13 per share.
F11 Represents a grant of options automatically granted pursuant to Recursion's Outside Director Compensation Policy. The shares subject to this option will vest and become exercisable as to 1/3rd of the shares subject to the award on the first three anniversaries of November 20, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.